Artivion, Inc. (AORT)
| Market Cap | 1.75B |
| Revenue (ttm) | 441.33M |
| Net Income (ttm) | 9.76M |
| Shares Out | 48.50M |
| EPS (ttm) | 0.21 |
| PE Ratio | 172.43 |
| Forward PE | 100.98 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 143,554 |
| Open | 37.26 |
| Previous Close | 37.03 |
| Day's Range | 36.06 - 37.41 |
| 52-Week Range | 23.04 - 48.25 |
| Beta | 1.62 |
| Analysts | Strong Buy |
| Price Target | 49.40 (+36.99%) |
| Earnings Date | May 7, 2026 |
About AORT
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branc... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for AORT stock is "Strong Buy." The 12-month stock price target is $49.4, which is an increase of 36.99% from the latest price.
News
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results
ATLANTA, April 23, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2026 financial results...
Artivion Announces U.S. FDA Approval of the NEXUS® Aortic Arch System
Endospan's NEXUS branched endovascular stent graft system shown to effectively treat aortic arch disease, including chronic aortic dissections ATLANTA, April 7, 2026 /PRNewswire/ -- Artivion, Inc. (NY...
Artivion Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
AMDS is driving accelerated stent graft growth, with 2026 focused on expanding account penetration and implant-driven revenue. On-X benefits from strong clinical data and market expansion, while NEXUS approval and acquisition are anticipated. Mature products remain steady, and new launches are set to boost margins and operating leverage.
Artivion to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
ATLANTA, March 3, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate virtually at the ...
Artivion Earnings Call Transcript: Q4 2025
Delivered 13% revenue and 26% adjusted EBITDA growth in 2025, with strong Q4 results led by stent grafts and On-X. 2026 guidance calls for 10%-14% revenue growth and 18%-22% adjusted EBITDA growth, supported by new product launches, clinical data, and ongoing margin expansion.
Artivion Reports Fourth Quarter and Full Year 2025 Financial Results
Fourth Quarter Highlights: GAAP revenue was $116.0 million in the fourth quarter of 2025 versus $97.3 million in the fourth quarter of 2024. For the full year, GAAP revenue was $441.3 million versus $...
Artivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual Meeting
1-Year Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate High Patient Survival with Low Morbidity 2-Year Data from the AMDS PERSEVERE IDE Trial Further Demonstrate the Persistent Clinical Bene...
Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter 2025 Financial Results
ATLANTA, Jan. 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter 2025 financial results...
Artivion Transcript: Stifel 2025 Healthcare Conference
Aortic-focused innovation and strategic acquisitions have built a robust product pipeline, driving double-digit revenue and margin expansion. AMDS and On-X are fueling growth, with new clinical data and reimbursement tailwinds, while operational and financial discipline support sustained performance.
Artivion Earnings Call Transcript: Q3 2025
Q3 2025 saw 16% revenue and 39% adjusted EBITDA growth, led by strong stent graft and On-X valve performance. Guidance for 2025 was raised, with double-digit growth expected to continue, supported by new product launches, clinical data, and expanded manufacturing capacity.
Artivion Reports Third Quarter 2025 Financial Results
Third Quarter Highlights: Achieved revenue of $113.4 million in the third quarter of 2025 versus $95.8 million in the third quarter of 2024, an increase of 18% on a GAAP basis and 16% on a non-GAAP co...
Artivion Announces Treatment of First Patient with Arcevo LSA in ARTIZEN Pivotal Trial
ATLANTA , Nov. 6, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the treatment of the first patient in the ...
Artivion to Participate in the Stifel 2025 Healthcare Conference
ATLANTA , Oct. 29, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate at the upcoming ...
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2025 Financial Results
ATLANTA , Oct. 23, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2025 financial results...
Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE and AMDS PROTECT Trials at the 39th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting
30-day Data from the AMDS PERSEVERE Trial Demonstrates Visceral Malperfusion Resolution in 83%, and Renal Malperfusion Resolution in 74% of Affected Subjects Post-AMDS Implantation Real-World Data fro...
Artivion Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Management outlined a strategy focused on aorta-related products, double-digit growth, and expanding EBITDA margins, driven by a robust PMA-protected pipeline. New product launches, especially in the U.S., are expected to accelerate growth and profitability, with international sales remaining strong.
Artivion to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference
ATLANTA , Sept. 5, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate at the upcoming ...
Artivion Transcript: Canaccord Genuity’s 45th Annual Growth Conference
Strong double-digit growth is driven by On-X and stent businesses, supported by robust clinical data and a de-risked pipeline targeting $1 billion in new opportunities. Financial performance is improving with expanding margins, positive cash flow, and a focus on deleveraging and strategic acquisitions.
Artivion Earnings Call Transcript: Q2 2025
Q2 2025 saw 14% revenue and 33% adjusted EBITDA growth, driven by strong On-X and AMDS performance, improved margins, and significant debt reduction. Full-year guidance was raised, with accelerating growth expected in H2 and robust pipeline progress.
Artivion Reports Second Quarter 2025 Financial Results
Second Quarter Highlights: Achieved revenue of $113.0 million in the second quarter of 2025 versus $98.0 million in the second quarter of 2024, an increase of 15% on a GAAP basis and 14% on a non-GAAP...
Artivion to Participate in Upcoming Investor Conferences
ATLANTA , July 30, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming ...
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2025 Financial Results
ATLANTA , July 24, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2025 financial result...
Artivion Transcript: 2025 Truist Securities MedTech Conference
Focused on aortic solutions, the company is launching high-margin products like AMDS and NEXUS, driving sequential growth and expanding global reach. Clinical data supports strong adoption, while operational leverage and reduced debt position the business for durable EBITDA and free cash flow growth.
Artivion Announces Closing of Transactions to Exchange $99.5 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock
ATLANTA , May 28, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the closing of transactions related to pre...
Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock
ATLANTA , May 14, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it entered into separate, privately n...